1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Novo Nordisk A/S - Strategy and SWOT Report

Novo Nordisk A/S - Strategy and SWOT Report

  • November 2015
  • -
  • MarketLine
  • -
  • 31 pages

Introduction

Novo Nordisk A/S - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Novo Nordisk A/S required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Novo Nordisk A/S in the form of a SWOT analysis

- An in-depth view of the business model of Novo Nordisk A/S including a breakdown and examination of key business segments

- Intelligence on Novo Nordisk A/S’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Novo Nordisk A/S, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Novo Nordisk (or 'the company') is a leading global provider of diabetes products. The company also has a leadership position in hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk operates in Europe, North America, China, Japan, Korea and other regions of the world. It is headquartered in Bagsvaerd, Denmark, and employed 41,450 people as of December 31, 2014. The company recorded revenues of DKK88,806 million (approximately $15,816.3 million) during the financial year ended December 2014 (FY2014), an increase of 6.3% over FY2013. The operating profit of the company was DKK34,492 million (approximately $6,143 million) in FY2014, an increase of 9.5% over FY2013. The net profit of the company was DKK26,481 million (approximately $4,716.3 million) in FY2014, an increase of 5.2% over FY2013.

Reasons to Purchase:

- Gain understanding of Novo Nordisk A/S and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Novo Nordisk A/S as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Novo Nordisk A/S’s business structure, strategy and prospects

Table Of Contents

Novo Nordisk A/S - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.